The agency expanded its previous premarket approvals for the catheter-based Impella 5.5 and CP pumps developed by Abiomed, for children weighing at least 30 kilograms and 52 kilograms for each ...
A spokesperson for Johnson & Johnson - which acquired Abiomed in 2022 - told Reuters: "This notification is not a device removal and Impella heart pumps remain on the market and available for ...
Impella 5.5 and Impella CP enable heart recovery as part of the world's smallest heart pump platform. Johnson & Johnson MedTech (Abiomed, Inc.) has partnered with the Advanced Cardiac Therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback